Quality Assurance Solutions for Ophthalmic Clinical Development
Inspection-Ready. Risk-Based. Sustainable.
Overview
PRN’s Quality Assurance services provide specialized support to pharmaceutical and biotechnology companies conducting ophthalmic clinical trials, aligning trial execution with regulatory and quality expectations.
By aligning with each sponsor’s development stage and real-world regulatory expectations, our solutions integrate quality proactively into daily operations—eliminating the need for reactive fixes during submissions or inspections.
Our Ophthalmology-Focused Approach
PRN applies a disciplined, fit-for-purpose approach to quality assurance, that reflects the unique scientific, operational, and regulatory considerations of ophthalmic clinical trials. Our approach is grounded in three guiding principles and executed through services designed to support inspection-ready ophthalmology programs.
Smart – Quality practices aligned to program risk, stage of development, and applicable regulatory expectations.
Simple – Clear procedures, well-defined deliverables, and practical documentation standards that enable consistent execution.
Sustainable – Scalable quality systems designed to grow with the organization, minimizing rework and late-stage remediation.
Quality is a shared responsibility. When roles, expectations, and processes are clearly defined, quality becomes an enabler of clinical execution— supporting progress rather than slowing it down.
Areas of Support
- Inspection readiness and audit preparedness across all stages of clinical development
- Risk-based quality management and sponsor oversight aligned with program complexity and regulatory expectations
- SOP development with auditable, clearly defined deliverables that support consistent implementation
- Training programs that support consistent execution and accountability and enable consistent execution across functions
- Vendor and functional service provider oversight frameworks to ensure compliance and performance alignment
- Identification, documentation, and resolution of errors and deviations using practical, regulator‑ready approaches
- Implementation and oversight of electronic clinical systems, including eTMF environments
Value to Sponsors
Quality deficiencies identified late in ophthalmic development can delay approvals, increase remediation costs, and raise concerns about the reliability of complex, image- and assessment-based data. In ophthalmology trials – where endpoints often rely on specialized procedures, imaging quality, and masked evaluations – late-stage quality gaps can be particularly difficult to correct.
By contrast, establishing sustainable, risk-based quality practices early enables sponsors to remain inspection-ready across all phases of development while supporting more efficient clinical execution. Proactive quality integration improves data integrity, strengthens sponsor oversight, and reduces the likelihood of disruptive findings during audits or regulatory inspections.
Key elements of PRN’s quality assurance approach are discussed in PRN’s Quality Assurance podcast, where industry experts share practical strategies for building inspection-ready systems early in ophthalmic development and advancing programs with confidence.